MCAS is a real clinical entity, but it is also the most over-diagnosed label in modern allergy/immunology. The single biggest reason is that two parallel "consensus" proposals disagree about how strict the criteria should be — and which one you use determines whether a patient with chronic multi-system symptoms has MCAS or "unexplained multisystem illness." Practitioners like Andra Sitoianu (@BioavailableNd) typically use the broader consensus-2 criteria.

01The two-consensus split

Consensus-1 (Valent/Akin/Weiler — JACI, 2019/2024 update)

The conservative criteria. A diagnosis of MCAS requires all three:

Typical clinical symptoms of mast cell activation in ≥2 organ systems (skin, GI, cardiovascular, respiratory, neurologic).
Objective biochemical evidence of mediator release during a symptomatic episode. Serum tryptase must rise by ≥20% over the patient's own baseline (sometimes stated as baseline + 2 ng/mL absolute), ideally measured within 1–2 hours of an acute flare.
Response to mast-cell-targeted therapy (H1/H2 antihistamines, cromolyn, leukotriene antagonists).[5][8][9][129]

Consensus-2 (Afrin/Molderings — Diagnosis 2020, JACI 2021)

The broader criteria. Allows diagnosis when chronic multi-system symptoms consistent with MC mediator release are present, with at least one objective biochemical correlate (tryptase, prostaglandin D2, heparin, chromogranin A, or other mediator), with or without an acute tryptase rise.[4][6] Afrin's group estimates MCAS prevalence "up to 17% of the general population."[4] The 2024 review notes "the field's two principal proposals differ so substantially in patient counts that diagnosis and treatment access depend on which one the clinician uses."[3]

Why the split matters

Patients meeting consensus-1 almost certainly have true MC mediator disease and a measurable biochemical signature.[5][8][129]
Patients meeting consensus-2 only are a heterogeneous mix: some have MCAS the field has not yet characterized, some have HIT vs MCAS today, some have functional disorders, some have primary psychiatric or somatic symptom presentations.[5][128]
A 2024 single-center study of 703 suspected MCAS patients found only a small minority met full consensus-1 criteria; most had alternative or comorbid explanations (chronic urticaria, hereditary α-tryptasemia, idiopathic anaphylaxis, somatization).[128]

02Mast cell mediator testing — what to order

Test	What it tells you	Caveat
Serum tryptase (baseline)	Reflects mast cell burden; >20 ng/mL is a minor WHO criterion for systemic mastocytosis.	Must be drawn outside an acute episode as a true baseline.[1][36][127]
Acute-flare tryptase	Rise of ≥20% over baseline during symptoms documents mediator release.	Timing is everything; misses if drawn >2–4 h after resolution.[5][8]
24-h urinary prostaglandin D2 (PGD2) or 11-β-PGF2α	Confirms arachidonic-pathway activation.	Less specific; expensive.[32]
N-methylhistamine (urine or plasma)	Histamine metabolite; elevated when histamine is released or when HIT is active.	Affected by diet (fermented foods, wine) and DAO activity.[12]
Chromogranin A	Generic neuroendocrine marker, often co-elevated with mast cell activation.	Elevated with PPIs, kidney disease, neuroendocrine tumors — high false-positive.
Bone marrow biopsy with tryptase IHC + KIT D816V mutation testing	Distinguishes systemic mastocytosis from MCAS.	Required if tryptase persistently >20 ng/mL or other mastocytosis criteria are met.[1][114]

Swipe table →

03Differential diagnosis checklist

A patient with multi-system "MCAS-like" symptoms should be evaluated for:

Systemic mastocytosis — tryptase >20 ng/mL + KIT D816V + mast cell aggregates on BM biopsy.[1][36]
Hereditary α-tryptasemia (HαT) — germline TPSAB1 copy-number gain; tryptase usually 8–20 ng/mL; associated with anaphylaxis, flushing, GI symptoms, joint hypermobility.[93][127][90][92]
Chronic spontaneous urticaria — has its own diagnostic and treatment pathway (omalizumab).[69]
Carcinoid syndrome — chromogranin A, 5-HIAA, octreotide scan.
Pheochromocytoma — plasma metanephrines, imaging.
Scombroid poisoning — acute histamine syndrome after spoiled fish.
Anaphylaxis with normal tryptase — idiopathic anaphylaxis is its own diagnosis.[76]
SIBO / IBS — mast cell density is increased in IBS mucosa (PMID 32649443); GI symptoms may improve with rifaximin or diet.[109]
Hypermobile EDS + dysautonomia (POTS) — clustered with MCAS; not the same.[147][71]
CIRS / mold illness — overlapping inflammatory markers; distinct protocol (Shoemaker).[28]
Somatic symptom disorder / functional neurological disorder — when no objective mediator release is documented.[3][5]

04HαT as a confounding variable

Hereditary α-tryptasemia is the single most important consideration when serum tryptase runs 8–20 ng/mL and the patient has anaphylaxis or flushing.[93][127] HαT is autosomal dominant with extra copies of TPSAB1; it is not MCAS, but the symptoms overlap heavily and HαT is much more common than previously recognized (carrier frequency roughly 5–6% in European-ancestry populations).[92][127] Treating presumed MCAS in HαT patients without acknowledging the underlying genetic condition is a common failure mode.[127]

05What the field agrees on (2026)

MCAS exists. Multiple international working groups have ratified criteria.[1][4][5][8]
MCAS should not be self-diagnosed. Documented biochemical mediator release and/or response to mast-cell-targeted therapy is the minimum standard.[3][5][128]
Consensus-1 is more restrictive, consensus-2 is more inclusive; both are used. Choice affects population prevalence estimates by an order of magnitude.[4]
Tryptase is the most useful single biomarker; baseline + flare pairing is the diagnostic test.[8][129]

06Method note

Sources are PubMed-indexed primary literature fetched 2026-10-15. The Valent 2019/2021 and Afrin 2020/2021 papers are the canonical sources for the two-consensus split.

07Notes

Most of the controversy is downstream of "what we count as MCAS." Restricting to consensus-1 produces fewer diagnoses, more conservative treatment, and stronger research cohorts; broadening to consensus-2 captures more patients but dilutes the research signal.
Andra Sitoianu's framing is consistent with consensus-2; many academic allergists use consensus-1. Patients who suspect MCAS should ask which criteria their provider used.
Tryptase alone cannot rule MCAS in or out; a normal tryptase does not exclude MCAS if other mediators are elevated.

08Connections

Neighborhood · 6 linked entriesOpen full map →

09Sources

PubMed 32649443PubMed 32649443
PubMed 34901755PubMed 34901755
PubMed 38243020PubMed 38243020
PubMed 32324159PubMed 32324159
PubMed 31470118PubMed 31470118
PubMed 32328892PubMed 32328892
PubMed 33261124PubMed 33261124
PubMed 35605594PubMed 35605594
PubMed 38674909PubMed 38674909
PubMed 36069791PubMed 36069791
PubMed 36863614PubMed 36863614
PubMed 39216803PubMed 39216803
PubMed 42807181PubMed 42807181
PubMed 40387691PubMed 40387691
PubMed 30961837PubMed 30961837
PubMed 42844895PubMed 42844895
PubMed 42793192PubMed 42793192
PubMed 42292655PubMed 42292655
PubMed 41399928PubMed 41399928
PubMed 41801525PubMed 41801525
PubMed 38056692PubMed 38056692
PubMed 23409940PubMed 23409940
PubMed 40352770PubMed 40352770

10Entry history

16 Oct 2026